Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
Hong Kong Chief Executive Carrie Lam announced at a press conference on Saturday that a contentious bill to allow extraditions to mainland China has been put on hold.China Politicsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
The prescription drugs that have seen the most rapid growth in cost in the U.S. don't treat depression, cholesterol or even autoimmune diseases.
Blockbuster male libido treatments Viagra and Cialis saw the biggest price hikes among the 17 top-selling brand-name drugs that have seen costs surges from 2012 through 2017, according to a new study published Friday in the peer-reviewed Journal of the American Medical Association.
Researchers from the Scripps Research Translational Institute analyzed six years of pharmacy claims data from the Blue Cross Blue Shield Axis, a database of more than 35 million individuals with private prescription drug insurance. They found there was a "near universal" increase in net prices of 49 brand-name drugs with 17 of those drugs seeing prices double over the time period.
The largest price increase came from Pfizer's Viagra, which surged by 190% over the six-year time period to $370 from $127 per prescription, according to the study. That was followed by Viagra rival Cialis, produced by Eli Lily, which rose by 187% to $365 from $127 for a prescription. Eli Lilly's osteoporosis drug Forteo came in third with a 177% price increase.
Nathan Wineinger, an assistant professor at Scripps Research and lead author of the study, said researchers didn't see any difference in cost increases between drugs that had been on the market for a significant period of time, were relatively new or a had a generic version. That "was disheartening," he said.
Researchers said they were were limited by a lack of information on drug price rebates and how they affected net prices. Additionally, researchers only examined drugs that have exceeded $500 million in U.S. sales or $1 billion in sales worldwide.
The study was funded with a grant from the National Institutes of Health National Center for Advancing Translational Sciences. Wineinger said Blue Cross Blue Shield had no influence over the study.
High drug costs have become a rare bipartisan issue in Washington with lawmakers on both sides of the aisle demanding something be done. President Donald Trump has made lowering prices one of the key issues of his administration. Democrats are jockeying to prove they can lead reform.
Earlier this month, the Trump administration announced pharmaceutical companies would be required to disclose the list price of their prescription medicines in television commercials as soon as this summer. Health and Human Services Secretary Alex Azar told CNBC that the administration hopes the cost disclosures will eventually shame drugmakers into lowering their prices.
Drugmakers have been resistant to advertising list prices, the price before rebates and discounts, saying it's simply the price that's advertised, and not what consumers actually pay.
Pharma executives have instead thrown their support behind a Trump administration proposal that would give consumers an estimated $29 billion in rebates now paid to pharmacy benefit managers. Drug manufacturers pay PBMs the rebates for getting their drugs covered by Medicare's Part D prescription plan.
The drugmakers weren't immediately available for comment.